2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T644,To emphasize the diagnostic value of cutaneous manifestations in disseminated invasive fungal disease (IFD). IFD carry high mortality and diagnosis is often delayed, while early recognition is crucial for patient outcomes. This review focuses on skin manifestations of fungi of highest relevance according to the WHO: Candida spp., Aspergillus spp., Mucorales, Fusarium spp., and Scedosporium spp. Cutaneous signs in disseminated candidiasis typically manifest as maculopapular or nodular lesions. Frequency and morphology vary depending on the Candida spp. involved. Secondary cutaneous aspergillosis presents with variable morphologies, including erythematous papules, ulcerative nodules, hemorrhagic bullae, or necrotic eschars, and may appear before standard diagnostic tests yield positive results. In invasive fusariosis, lesions typically present as vesicles or papules and progress to necrotic eschars. The morphology of skin manifestations of generalized mucormycosis varies according to the underlying disease. The formation of a necrotic eschar is considered pathognomonic. In disseminated scedosporiosis, cutaneous manifestations include ecchymoses, hemorrhagic bullae, necrotic papules, ulcers, or infiltrative plaques, often resembling infections with aspergillosis or fusariosis. Diagnosis requires a multimodal approach combining histopathology, microbiological cultures and nonculture-based assays. Despite the variability in frequency and presentation, cutaneous manifestations provide a valuable clinical clue in disseminated IFD and may facilitate early recognition and intervention.31:T9ff, Purpose of review To emphasize the diagnostic value of cutaneous manifestations in disseminated invasive fungal disease (IFD). IFD carry high mortality and diagnosis is often delayed, while early recognition is crucial for patient outcomes. This review focuses on skin manifestations of fungi of highest relevance according to the WHO: Candida spp., Aspergillus spp., Mucorales, Fusarium spp., and Scedosporium spp. Recent findings Cutaneous signs in disseminated candidiasis typically manifest as maculopapular or nodular lesions. Frequency and morphology vary depending on the Candida spp. involved. Secondary cutaneous aspergillosis presents with variable morphologies, including erythematous papules, ulcerative nodules, hemorrhagic bullae, or necrotic eschars, and may appear before standard diagnostic tests yield positive results. In invasive fusariosis, lesions typically present as vesicles or papules and progress to necrotic eschars. The morphology of skin manifestations of generalized mucormycosis varies according to the underlying disease. The formation of a necrotic eschar is considered pathognomonic. In disseminated scedosporiosis, cutaneous manifestations include ecchymoses, hemorrhagic bullae, necrotic papules, ulcers, or infiltrative plaques, often resembling infections with aspergillosis or fusariosis. Diagnosis requires a multimodal approach combining histopathology, microbiological cultures and nonculture-based assays. Summary Despite the variability in frequency and presentation, cutaneous manifestations provide a valuable clinical clue in disseminated IFD and may facilitate early recognition and intervention. 32:T845,The fungal diagnostic landscape is evolving; whereas previously, traditional culture-based methods dominated, most invasive fungal disease is now diagnosed with non-culture-based tests, including direct microscopy, antigen, antibody, and molecular assays, supported by histopathology and radiology. Access to and turnaround time of diagnostic tests and their clinical implementation varies across the UK. The British Society for Medical Mycology convened an expert group to update its 2015 best practice guidance. Guidance on histopathology and radiology investigations remain unchanged from the 2015 standards of care. For each mycological test, we include test-specific commentaries and accompanying tables, with expected turnaround times (sample collection to reporting). Based on recent evidence, new or stronger recommendations include use of Pneumocystis PCR; 1,3-β-D-glucan testing for suspected invasive candidiasis and Pneumocystis pneumonia; higher volume respiratory sample cultures; Aspergillus antigen or antibody-based testing in expanded clinically vulnerable populations, including patients in intensive care units and patients with chronic respiratory disease (including asthma); use of Candida PCR and Mucorales PCR in specific contexts; pan-fungal PCR and DNA sequencing for fungal identification from positive microscopy or histopathology specimens; and inclusion of posaconazole and isavuconazole in therapeutic antifungal monitoring recommendations. We discuss integration of diagnostic tests with antifungal stewardship and common clinical scenarios. Although recommendations focus on adults and UK practice, use in paediatric populations and worldwide applicability is discussed. Recommendations are presented as auditable standards to facilitate implementation and quality improvement measures. An emphasis on integration of combined diagnostics with antifungal stewardship and clinical pathways extends guideline relevance beyond microbiology laboratories to clinicians investigating patients with multimorbidity and suspected fungal disease within increasingly complex health-care systems.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Invasive Candidiasis: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Invasive Candidiasis (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Invasive%20Candidiasis\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Invasive Candidiasis\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Invasive%20Candidiasis\"}]}}"}}]],["$","$L2f",null,{"title":"Invasive Candidiasis: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Invasive Candidiasis with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1080/14787210.2026.2710718","pmid":"42505243","title":"Management of invasive fungal infections in the intensive care unit","journal_title":"Expert Review of Anti-infective Therapy","journal_issn":"1478-7210","published_at":"2026-07-28T00:00:00.000Z","url":"https://doi.org/10.1080/14787210.2026.2710718","source_score":41,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-04T18:18:00.377Z","updated_at":"2026-08-04T18:18:00.377Z","tags":[{"paper_doi":"10.1080/14787210.2026.2710718","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1080/14787210.2026.2710718","tag_type":"category","value":"Infectious Diseases","value_numeric":null},{"paper_doi":"10.1080/14787210.2026.2710718","tag_type":"condition","value":"Invasive Candidiasis","value_numeric":null},{"paper_doi":"10.1080/14787210.2026.2710718","tag_type":"condition","value":"Invasive Fungal Infection","value_numeric":null},{"paper_doi":"10.1080/14787210.2026.2710718","tag_type":"condition","value":"Invasive Pulmonary Aspergillosis","value_numeric":null},{"paper_doi":"10.1080/14787210.2026.2710718","tag_type":"condition","value":"Mucormycosis","value_numeric":null},{"paper_doi":"10.1080/14787210.2026.2710718","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1080/14787210.2026.2710718","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1080/14787210.2026.2710718","tag_type":"modality","value":"Antifungal Therapy","value_numeric":null},{"paper_doi":"10.1080/14787210.2026.2710718","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1080/14787210.2026.2710718","tag_type":"warning","value":"Age group tagged as 'adult' based on ICU context; the review does not explicitly restrict to adults or report pediatric ICU data.","value_numeric":null},{"paper_doi":"10.1080/14787210.2026.2710718","tag_type":"warning","value":"No sample size applies — this is a narrative review with no primary patient cohort.","value_numeric":null},{"paper_doi":"10.1080/14787210.2026.2710718","tag_type":"warning","value":"The paper is dated 2026; some cited evidence or diagnostic criteria may reflect very recent or provisional guidelines not yet widely adopted.","value_numeric":null}],"summaries":{"what_studied":"This narrative review evaluates the epidemiology, risk factors, diagnostic strategies, and management of invasive fungal infections (IFI) — including invasive pulmonary aspergillosis, invasive candidiasis, and mucormycosis — in critically ill ICU patients, with emphasis on non-culture-based diagnostics and ICU-specific treatment considerations.","key_result":"IFI in the ICU increasingly affects both immunocompromised and non-immunocompromised patients and carries substantial mortality; the review supports an individualized approach combining early clinical risk stratification, targeted culture and non-culture-based testing, and timely antifungal therapy initiation.","limitations":"Narrative review design limits systematic evidence synthesis; molecular diagnostics lack large ICU-cohort validation; histopathological confirmation is frequently unfeasible in ICU patients, forcing reliance on probabilistic diagnostic criteria.","practice_takeaway":"Use clinical risk stratification to guide early suspicion of IFI in ICU patients — not just those who are immunocompromised. Pair targeted non-culture-based diagnostics with prompt antifungal therapy rather than waiting for culture confirmation."}},{"doi":"10.1084/jem.20260530","pmid":"42479027","title":"Tissue-type plasminogen activator protects against kidney damage in invasive fungal infection","journal_title":"Journal of Experimental Medicine","journal_issn":"0022-1007","published_at":"2026-07-21T00:00:00.000Z","url":"https://doi.org/10.1084/jem.20260530","source_score":8,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-29T13:31:13.924Z","updated_at":"2026-07-29T13:31:13.924Z","tags":[{"paper_doi":"10.1084/jem.20260530","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1084/jem.20260530","tag_type":"category","value":"Immunology","value_numeric":null},{"paper_doi":"10.1084/jem.20260530","tag_type":"condition","value":"Acute Kidney Injury","value_numeric":null},{"paper_doi":"10.1084/jem.20260530","tag_type":"condition","value":"Candida Albicans Infection","value_numeric":null},{"paper_doi":"10.1084/jem.20260530","tag_type":"condition","value":"Invasive Candidiasis","value_numeric":null},{"paper_doi":"10.1084/jem.20260530","tag_type":"generic","value":"alteplase","value_numeric":null},{"paper_doi":"10.1084/jem.20260530","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1084/jem.20260530","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1084/jem.20260530","tag_type":"modality","value":"Fibrinolytic Agent","value_numeric":null},{"paper_doi":"10.1084/jem.20260530","tag_type":"study_design","value":"Preclinical Animal Study","value_numeric":null},{"paper_doi":"10.1084/jem.20260530","tag_type":"warning","value":"The impact_flag 'practice_changing' reflects a novel mechanistic finding and a proposed repurposing of an approved drug, but all evidence comes from mouse models — no human clinical data are presented. Clinical applicability remains speculative. The study uses a nonenzymatic tPA form distinct from standard clinical alteplase; the exact agent's clinical availability is not confirmed in the paper.","value_numeric":null}],"summaries":{"what_studied":"This study investigated whether tissue-type plasminogen activator (tPA) protects the kidney during invasive *Candida albicans* infection (candidiasis), focusing on its signaling through LRP1 in renal tubular epithelial cells (RTEC) and its effect on apoptosis and organ damage.","key_result":"tPA — induced by IL-17 and TNFα in renal endothelial cells and RTEC — activates ERK1/2 via LRP1 to suppress RTEC apoptosis; mice with RTEC-specific LRP1 deletion showed worsened kidney damage during candidiasis, and a nonenzymatic (non-clot-dissolving) tPA form recapitulated this protection.","limitations":"Findings are primarily from mouse models; direct translation to human candidiasis patients is not yet established. The nonenzymatic tPA form used has not been tested in clinical candidiasis settings. The study does not address systemic bleeding risk or other off-target effects of tPA in this context.","practice_takeaway":"The tPA/LRP1 axis is a novel renal-protective pathway in invasive candidiasis; clinically approved tPA (in a nonenzymatic form) may warrant investigation as an adjunct to limit kidney injury in patients with invasive fungal infections."}},{"doi":"10.1111/myc.70205","pmid":"42460544","title":"Rezafungin Versus Caspofungin in Candidaemia and Invasive Candidiasis: A Post Hoc Pooled Analysis of Phase 2 and Phase 3 Trials","journal_title":"Mycoses","journal_issn":"0933-7407","published_at":"2026-07-16T00:00:00.000Z","url":"https://doi.org/10.1111/myc.70205","source_score":3,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-25T13:57:56.314Z","updated_at":"2026-07-25T13:57:56.314Z","tags":[{"paper_doi":"10.1111/myc.70205","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1111/myc.70205","tag_type":"brand","value":"Rezzayo","value_numeric":null},{"paper_doi":"10.1111/myc.70205","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/myc.70205","tag_type":"condition","value":"Candidaemia","value_numeric":null},{"paper_doi":"10.1111/myc.70205","tag_type":"condition","value":"Invasive Candidiasis","value_numeric":null},{"paper_doi":"10.1111/myc.70205","tag_type":"generic","value":"caspofungin","value_numeric":null},{"paper_doi":"10.1111/myc.70205","tag_type":"generic","value":"rezafungin","value_numeric":null},{"paper_doi":"10.1111/myc.70205","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1111/myc.70205","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1111/myc.70205","tag_type":"modality","value":"Echinocandin","value_numeric":null},{"paper_doi":"10.1111/myc.70205","tag_type":"sample_size","value":"n=372","value_numeric":372},{"paper_doi":"10.1111/myc.70205","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1111/myc.70205","tag_type":"study_design","value":"Post Hoc Pooled Analysis of Randomized Controlled Trials","value_numeric":null},{"paper_doi":"10.1111/myc.70205","tag_type":"warning","value":"The mITT population (n=339) is smaller than the total enrolled population (n=372) due to patients not meeting modified intent-to-treat criteria; efficacy results apply to the mITT group.","value_numeric":null},{"paper_doi":"10.1111/myc.70205","tag_type":"warning","value":"The study_design is a post hoc pooled analysis of Phase 2 and Phase 3 RCTs; it was not prospectively powered for the pooled comparisons, and subgroup findings (e.g., older adults, renal insufficiency) should be interpreted as hypothesis-generating only.","value_numeric":null},{"paper_doi":"10.1111/myc.70205","tag_type":"warning","value":"Two authors (Dickerson, Cox) are employees of the funder (Mundipharma Research Limited), which co-funded the ReSTORE trial and provided medical writing support — potential industry bias should be noted.","value_numeric":null}],"summaries":{"what_studied":"Post hoc pooled analysis of adults with candidaemia or invasive candidiasis (IC) from the Phase 2 STRIVE and Phase 3 ReSTORE trials (including the ReSTORE China cohort), comparing once-weekly IV rezafungin 400/200 mg vs. once-daily IV caspofungin 70/50 mg for up to 4 weeks (mITT population: n=339).","key_result":"Day-30 all-cause mortality was 20% (33/161) with rezafungin vs. 22% (39/178) with caspofungin (weighted difference −2.4%, 95% CI −11.2 to 6.4), confirming non-inferiority. Median time to negative blood culture was shorter with rezafungin (23.1 h vs. 36.7 h; p=0.0073). In patients ≥65 years, Day-30 mortality was 18% vs. 34% in favour of rezafungin (weighted difference −16.3%, 95% CI −30.6 to −1.9).","limitations":"- Post hoc pooled analysis; not powered for subgroup comparisons, which should be considered exploratory.\n- Excludes paediatric patients and complex IC forms (endocarditis, CNS, osteomyelitis), limiting generalisability.\n- Methodological differences between STRIVE and ReSTORE (AE grading, step-down dosing, MIC protocols) may introduce heterogeneity despite statistical adjustment.","practice_takeaway":"Rezafungin is non-inferior to caspofungin for 30-day mortality in candidaemia/IC and clears blood cultures faster—a potential advantage in critically ill patients, older adults, and those with renal insufficiency. Clinicians can use rezafungin's once-weekly dosing as a practical alternative to daily caspofungin, particularly in ICU settings."}},{"doi":"10.1016/j.cmi.2026.05.033","pmid":"42219031","title":"Glucocorticoid use and candidemia: results from a nationwide case-control study","journal_title":"Clinical Microbiology and Infection","journal_issn":"1198-743X","published_at":"2026-05-30T00:00:00.000Z","url":"https://doi.org/10.1016/j.cmi.2026.05.033","source_score":18,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-11T13:42:30.043Z","updated_at":"2026-06-11T13:42:30.043Z","tags":[{"paper_doi":"10.1016/j.cmi.2026.05.033","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.cmi.2026.05.033","tag_type":"category","value":"Infectious Diseases","value_numeric":null},{"paper_doi":"10.1016/j.cmi.2026.05.033","tag_type":"condition","value":"Candidemia","value_numeric":null},{"paper_doi":"10.1016/j.cmi.2026.05.033","tag_type":"condition","value":"Chronic Pulmonary Disease","value_numeric":null},{"paper_doi":"10.1016/j.cmi.2026.05.033","tag_type":"condition","value":"Inflammatory Bowel Disease","value_numeric":null},{"paper_doi":"10.1016/j.cmi.2026.05.033","tag_type":"condition","value":"Invasive Candidiasis","value_numeric":null},{"paper_doi":"10.1016/j.cmi.2026.05.033","tag_type":"condition","value":"Rheumatic Disease","value_numeric":null},{"paper_doi":"10.1016/j.cmi.2026.05.033","tag_type":"generic","value":"prednisolone","value_numeric":null},{"paper_doi":"10.1016/j.cmi.2026.05.033","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.cmi.2026.05.033","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.cmi.2026.05.033","tag_type":"modality","value":"Glucocorticoid","value_numeric":null},{"paper_doi":"10.1016/j.cmi.2026.05.033","tag_type":"sample_size","value":"n=67969","value_numeric":67969},{"paper_doi":"10.1016/j.cmi.2026.05.033","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.cmi.2026.05.033","tag_type":"study_design","value":"Case-Control Study","value_numeric":null},{"paper_doi":"10.1016/j.cmi.2026.05.033","tag_type":"warning","value":"C. dubliniensis was the only species where the association did not reach statistical significance — this subgroup was likely underpowered rather than truly different biologically.","value_numeric":null},{"paper_doi":"10.1016/j.cmi.2026.05.033","tag_type":"warning","value":"Sample size of n=67,969 represents combined cases (6,179) and controls (61,790); the case count alone is 6,179.","value_numeric":null},{"paper_doi":"10.1016/j.cmi.2026.05.033","tag_type":"warning","value":"The impact_flag 'practice_changing' reflects a large, well-powered national study with a strong dose-response, but the observational design means causality cannot be confirmed — confounding by indication (sicker patients receiving more steroids) may inflate estimates.","value_numeric":null}],"summaries":{"what_studied":"This nationwide Danish registry-based case-control study (2010–2024) examined whether oral glucocorticoid use within 90 days was associated with candidemia risk in adults, comparing 6,179 first-time Candida bloodstream infection cases to 61,790 matched population controls, with analyses by cumulative dose, Candida species, and underlying disease.","key_result":"Oral glucocorticoid use roughly doubled the odds of candidemia overall (aOR 2.17, 95% CI 1.92–2.45), with a clear dose-response: <750 mg prednisolone-equivalent (aOR 1.59), 750–1500 mg (aOR 2.25), and >1500 mg (aOR 5.23). Risk was highest in inflammatory bowel disease (aOR 4.62), rheumatic disease (aOR 3.15), and chronic pulmonary disease (aOR 2.07).","limitations":"- Observational design cannot exclude residual confounding from unmeasured severity of underlying illness (confounding by indication).\n- Only oral glucocorticoids captured via prescription redemption; inhaled, topical, or IV routes were not assessed.\n- Single-country registry data may limit generalizability to other healthcare settings.","practice_takeaway":"Patients on oral glucocorticoids — especially those with IBD, rheumatic disease, or chronic lung disease receiving high cumulative doses (>1500 mg prednisolone-equivalent) — carry substantially elevated candidemia risk and warrant heightened clinical vigilance for invasive fungal infection. Consider prompt diagnostic workup for candidemia when these patients present with unexplained fever or sepsis."}},{"doi":"10.1097/qco.0000000000001180","pmid":"41505800","title":"Skin signs of invasive fungal diseases: diagnostic clues for clinicians","journal_title":"Current Opinion in Infectious Diseases","journal_issn":"0951-7375","published_at":"2026-01-08T00:00:00.000Z","url":"https://doi.org/10.1097/qco.0000000000001180","source_score":20,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-01-13","doi":"10.1097/qco.0000000000001180","days":"7","issn":"0951-7375","rank":"6","field":"Clinical Medicine","score":"20","category":"Infectious Diseases","categories":["Infectious Diseases"],"_categories":["Infectious Diseases"]},"pubmed":{"doi":"10.1097/QCO.0000000000001180","title":"Skin signs of invasive fungal diseases: diagnostic clues for clinicians.","journal":"Current opinion in infectious diseases","methods":"","results":"","abstract":"$30","keywords":["angioinvasive molds","cutaneous signs","diagnostic clues","disseminated fungal infections","infections in immunocompromised"],"pubmed_id":"41505800","conclusions":"","publication_date":"2026-01-08T00:00:00"},"crossref":{"DOI":"10.1097/qco.0000000000001180","URL":"https://doi.org/10.1097/qco.0000000000001180","ISSN":["0951-7375","1473-6527"],"link":[{"URL":"https://journals.lww.com/10.1097/QCO.0000000000001180","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Skin signs of invasive fungal diseases: diagnostic clues for clinicians"],"author":[{"given":"Susanne","family":"Fadlalla","sequence":"first","affiliation":[{"name":"Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Faculty of Medicine, University of Cologne"},{"name":"Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), European Confederation for Medical Mycology (ECMM) Excellence Center, University Hospital Cologne"},{"name":"German Centre for Infection Research (DZIF), partner site Bonn-Cologne, Cologne, Germany; Clinical Trials Centre Cologne (ZKS Köln), Faculty of Medicine, University of Cologne"}]},{"given":"Rosanne","family":"Sprute","sequence":"additional","affiliation":[{"name":"Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Faculty of Medicine, University of Cologne"},{"name":"Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), European Confederation for Medical Mycology (ECMM) Excellence Center, University Hospital Cologne"},{"name":"German Centre for Infection Research (DZIF), partner site Bonn-Cologne, Cologne, Germany; Clinical Trials Centre Cologne (ZKS Köln), Faculty of Medicine, University of Cologne"}]},{"given":"Philipp","family":"Koehler","sequence":"additional","affiliation":[{"name":"Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Faculty of Medicine, University of Cologne"},{"name":"Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), European Confederation for Medical Mycology (ECMM) Excellence Center, University Hospital Cologne"},{"name":"Division of Clinical Immunology, Department I of Internal Medicine, University Hospital Cologne, Faculty of Medicine, University of Cologne and Center for Integrated Oncology (CIO) Aachen Bonn Cologne Duesseldorf, Cologne, Germany"}]},{"given":"Harald","family":"Seifert","sequence":"additional","affiliation":[{"name":"Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Faculty of Medicine, University of Cologne"},{"name":"German Centre for Infection Research (DZIF), partner site Bonn-Cologne, Cologne, Germany; Clinical Trials Centre Cologne (ZKS Köln), Faculty of Medicine, University of Cologne"},{"name":"Institute for Medical Microbiology, Immunology, and Hygiene, Faculty of Medicine and University Hospital Cologne, Cologne, Germany"}]},{"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[{"name":"Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Faculty of Medicine, University of Cologne"},{"name":"Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), European Confederation for Medical Mycology (ECMM) Excellence Center, University Hospital Cologne"},{"name":"German Centre for Infection Research (DZIF), partner site Bonn-Cologne, Cologne, Germany; Clinical Trials Centre Cologne (ZKS Köln), Faculty of Medicine, University of Cologne"},{"name":"Division of Clinical Immunology, Department I of Internal Medicine, University Hospital Cologne, Faculty of Medicine, University of Cologne and Center for Integrated Oncology (CIO) Aachen Bonn Cologne Duesseldorf, Cologne, Germany"}]}],"issued":{"date-parts":[[2025,12,30]]},"member":"276","prefix":"10.1097","source":"Crossref","volume":null,"created":{"date-time":"2026-01-08T23:00:09Z","timestamp":1767913209000,"date-parts":[[2026,1,8]]},"indexed":{"date-time":"2026-01-09T03:31:15Z","timestamp":1767929475178,"date-parts":[[2026,1,9]]},"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://journals.lww.com/10.1097/QCO.0000000000001180"}},"subtitle":[],"deposited":{"date-time":"2026-01-08T23:00:13Z","timestamp":1767913213000,"date-parts":[[2026,1,8]]},"issn-type":[{"type":"print","value":"0951-7375"},{"type":"electronic","value":"1473-6527"}],"published":{"date-parts":[[2025,12,30]]},"publisher":"Ovid Technologies (Wolters Kluwer Health)","reference":[{"DOI":"10.1016/j.cmi.2017.08.016","key":"R2-20260108","year":"2018","issue":null,"author":"Guarana","volume":"24","first-page":"246","unstructured":null,"article-title":"Acute disseminated candidiasis with skin lesions: a systematic review","journal-title":"Clin Microbiol Infect","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2018.04.059","key":"R3-20260108","year":"2019","issue":null,"author":"Shields","volume":"80","first-page":"869","unstructured":null,"article-title":"Angioinvasive fungal infections impacting the skin: background, epidemiology, and clinical presentation","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.17966/JMI.2021.26.4.83","key":"R4-20260108","year":"2021","issue":null,"author":"Park","volume":"26","first-page":"83","unstructured":null,"article-title":"Diagnosis and treatment of cutaneous aspergillosis","journal-title":"J Mycol Infect","doi-asserted-by":"crossref"},{"DOI":"10.1046/j.1365-2133.1998.02424.x","key":"R5-20260108","year":"1998","issue":null,"author":"Galimberti","volume":"139","first-page":null,"unstructured":null,"article-title":"Cutaneous aspergillosis: a report of six cases","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":null,"key":"R6-20260108","year":"2001","issue":null,"author":"Tobin","volume":"63","first-page":"326","unstructured":null,"article-title":"Sporotrichoid lymphocutaneous infections: etiology, diagnosis and therapy","journal-title":"Am Fam Physician","doi-asserted-by":null},{"DOI":"10.1038/sj.bmt.1702835","key":"R7-20260108","year":"2001","issue":null,"author":"Schimmelpfennig","volume":"27","first-page":"753","unstructured":null,"article-title":"Skin involvement as the first manifestation of systemic aspergillosis in patients after allogeneic hematopoietic cell transplantation","journal-title":"Bone Marrow Transplant","doi-asserted-by":"crossref"},{"DOI":"10.1038/sj.bmt.1703250","key":"R8-20260108","year":"2001","issue":null,"author":"Cornely","volume":"28","first-page":"899","unstructured":null,"article-title":"A novel type of metastatically spreading subcutaneous aspergillosis without epidermal lesions following allogeneic stem cell transplantation","journal-title":"Bone Marrow Transplant","doi-asserted-by":"crossref"},{"DOI":"10.1007/s12070-023-03707-3","key":"R9-20260108","year":"2023","issue":null,"author":"Arora","volume":"75","first-page":"1","unstructured":null,"article-title":"Secondary cutaneous mucormycosis – retrospective analysis from tertiary care hospital","journal-title":"Indian J Otolaryngol Head Neck Surg","doi-asserted-by":"crossref"},{"DOI":"10.1007/s12281-015-0236-z","key":"R10-20260108","year":"2015","issue":null,"author":"Bonifaz","volume":"9","first-page":"229","unstructured":null,"article-title":"Cutaneous mucormycosis: mycological, clinical, and therapeutic aspects","journal-title":"Curr Fungal Infect Rep","doi-asserted-by":"crossref"},{"DOI":"10.1093/cid/cir865","key":"R11-20260108","year":"2012","issue":"(Suppl 1)","author":"Ibrahim","volume":"54","first-page":"S16","unstructured":null,"article-title":"Pathogenesis of mucormycosis","journal-title":"Clin Infect Dis","doi-asserted-by":"crossref"},{"DOI":null,"key":"R12-20260108","year":"2019","issue":null,"author":"Menzinger","volume":"6","first-page":"275","unstructured":null,"article-title":"Cutaneous mucormycosis resulting from hematogenous dissemination of Rhizomucor pusillus in an immunocompromised patient","journal-title":"Dermatopathology","doi-asserted-by":null},{"DOI":"10.1016/S1473-3099(19)30312-3","key":"R13-20260108","year":"2019","issue":null,"author":"Cornely","volume":"19","first-page":"e405","unstructured":null,"article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","journal-title":"Lancet Infect Dis","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1439-0507.2009.01837.x","key":"R14-20260108","year":"2010","issue":"s1","author":"Seyfarth","volume":"53","first-page":"5","unstructured":null,"article-title":"Fusarium als Verursacher dermatologischer Krankheitsbilder","journal-title":"Mycoses","doi-asserted-by":"crossref"},{"DOI":"10.1093/ofid/ofae068","key":"R15-20260108","year":"2024","issue":null,"author":"Matsuo","volume":"11","first-page":"ofae068","unstructured":null,"article-title":"Adjunct terbinafine in patients with leukemia and invasive fusariosis with skin lesions: discordance between responses of skin lesions and systemic outcomes","journal-title":"Open Forum Infect Dis","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1445-5994.2008.01725.x","key":"R16-20260108","year":"2008","issue":null,"author":"Thursky","volume":"38","first-page":"496","unstructured":null,"article-title":"Recommendations for the treatment of established fungal infections","journal-title":"Intern Med J","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00277-003-0795-x","key":"R17-20260108","year":"2004","issue":null,"author":"Rothe","volume":"83","first-page":"394","unstructured":null,"article-title":"Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B","journal-title":"Ann Hematol","doi-asserted-by":"crossref"},{"DOI":"10.1093/mmy/myx113","key":"R18-20260108","year":"2018","issue":"(Suppl 1)","author":"Ramirez-Garcia","volume":"56","first-page":"S102","unstructured":null,"article-title":"Scedosporium and Lomentospora: an updated overview of underrated opportunists","journal-title":"Med Mycol","doi-asserted-by":"crossref"},{"DOI":"10.1080/1040841X.2018.1514366","key":"R19-20260108","year":"2019","issue":null,"author":"Seidel","volume":"45","first-page":"1","unstructured":null,"article-title":"Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope®","journal-title":"Crit Rev Microbiol","doi-asserted-by":"crossref"},{"DOI":"10.1128/cmr.00004-23","key":"R20-20260108","year":"2024","issue":null,"author":"Neoh","volume":"37","first-page":"e00012","unstructured":null,"article-title":"Scedosporiosis and lomentosporiosis: modern perspectives on these difficult-to-treat rare mold infections","journal-title":"Clin Microbiol Rev","doi-asserted-by":"crossref"},{"DOI":"10.1002/ski2.188","key":"R21-20260108","year":"2023","issue":null,"author":"Born","volume":"3","first-page":"e188","unstructured":null,"article-title":"A case of cutaneousScedosporium apiospermum infection in a patient on a Janus kinase inhibitor","journal-title":"Skin Health Dis","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2018.04.058","key":"R22-20260108","year":"2019","issue":null,"author":"Berger","volume":"80","first-page":"883","unstructured":null,"article-title":"Angioinvasive fungal infections impacting the skin: diagnosis, management, and complications","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"}],"short-title":[],"update-policy":"https://doi.org/10.1097/lww.0000000000001000","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Current Opinion in Infectious Diseases"],"reference-count":21,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,12,30]]},"references-count":21,"short-container-title":[],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1097/qco.0000000000001180","is_oa":false,"title":"Skin signs of invasive fungal diseases: diagnostic clues for clinicians","updated":"2026-01-10T04:46:20+00:00","published_date":"2025-12-30","best_oa_location":null}},"created_at":"2026-01-16T11:56:46.634Z","updated_at":"2026-01-20T15:55:50.695Z","tags":[{"paper_doi":"10.1097/qco.0000000000001180","tag_type":"category","value":"Infectious Diseases","value_numeric":null},{"paper_doi":"10.1097/qco.0000000000001180","tag_type":"condition","value":"Aspergillosis","value_numeric":null},{"paper_doi":"10.1097/qco.0000000000001180","tag_type":"condition","value":"Fusariosis","value_numeric":null},{"paper_doi":"10.1097/qco.0000000000001180","tag_type":"condition","value":"Invasive Candidiasis","value_numeric":null},{"paper_doi":"10.1097/qco.0000000000001180","tag_type":"condition","value":"Mucormycosis","value_numeric":null},{"paper_doi":"10.1097/qco.0000000000001180","tag_type":"condition","value":"Scedosporiosis","value_numeric":null},{"paper_doi":"10.1097/qco.0000000000001180","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1097/qco.0000000000001180","tag_type":"warning","value":"Design appears to be a narrative review rather than a systematic review.","value_numeric":null},{"paper_doi":"10.1097/qco.0000000000001180","tag_type":"warning","value":"No sample size or quantitative outcome data are provided.","value_numeric":null},{"paper_doi":"10.1097/qco.0000000000001180","tag_type":"warning","value":"Some morphologies overlap between pathogens (e.g., scedosporiosis resembling aspergillosis or fusariosis), limiting specificity.","value_numeric":null}],"summaries":{"what_studied":"Review of cutaneous manifestations that signal disseminated invasive fungal disease, focusing on Candida spp., Aspergillus spp., Mucorales, Fusarium spp., and Scedosporium spp., and outlining a multimodal diagnostic approach.","key_result":"Characteristic patterns include: candidiasis—maculopapular or nodular lesions; aspergillosis—erythematous papules, ulcerative nodules, hemorrhagic bullae, or necrotic eschars that may precede standard test positivity; fusariosis—vesicles or papules progressing to necrotic eschars; mucormycosis—variable lesions with a necrotic eschar considered pathognomonic; scedosporiosis—ecchymoses, hemorrhagic bullae, necrotic papules, ulcers, or infiltrative plaques, often mimicking aspergillosis or fusariosis.","limitations":"Narrative review without quantitative data on lesion frequency or diagnostic accuracy. Scope limited to WHO-prioritized fungi; other pathogens are not addressed.","practice_takeaway":"In patients with suspected disseminated IFD, inspect the skin for these patterns—especially necrotic eschars—and pursue a multimodal workup with histopathology, culture, and nonculture-based assays. Recognize that skin lesions in aspergillosis may appear before standard tests turn positive, prompting earlier evaluation."}},{"doi":"10.1016/s1473-3099(25)00550-x","pmid":"41232547","title":"British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases: 2025 update","journal_title":"The Lancet Infectious Diseases","journal_issn":"1473-3099","published_at":"2025-11-14T00:00:00.000Z","url":"https://doi.org/10.1016/s1473-3099(25)00550-x","source_score":112,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-12-02","doi":"10.1016/s1473-3099(25)00550-x","days":"30","issn":"1473-3099","rank":"4","field":"Clinical Medicine","score":"112","category":"Infectious Diseases","categories":["Infectious Diseases"],"_categories":["Infectious Diseases"]},"pubmed":{"doi":"10.1016/S1473-3099(25)00550-X","title":"British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases: 2025 update.","journal":"The Lancet. Infectious diseases","methods":"","results":"","abstract":"$32","keywords":[],"pubmed_id":"41232547","conclusions":"","publication_date":"2025-11-14T00:00:00"},"crossref":{"DOI":"10.1016/s1473-3099(25)00550-x","URL":"https://doi.org/10.1016/s1473-3099(25)00550-x","ISSN":["1473-3099"],"link":[{"URL":"https://api.elsevier.com/content/article/PII:S147330992500550X?httpAccept=text/xml","content-type":"text/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://api.elsevier.com/content/article/PII:S147330992500550X?httpAccept=text/plain","content-type":"text/plain","content-version":"vor","intended-application":"text-mining"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases: 2025 update"],"author":[{"given":"Silke","family":"Schelenz","sequence":"first","affiliation":[]},{"given":"Alireza","family":"Abdolrasouli","sequence":"additional","affiliation":[]},{"given":"Darius","family":"Armstrong-James","sequence":"additional","affiliation":[]},{"given":"H Ruth","family":"Ashbee","sequence":"additional","affiliation":[]},{"given":"Richard","family":"Barton","sequence":"additional","affiliation":[]},{"given":"Tihana","family":"Bicanic","sequence":"additional","affiliation":[]},{"given":"Andy","family":"Borman","sequence":"additional","affiliation":[]},{"given":"Lottie","family":"Brown","sequence":"additional","affiliation":[]},{"given":"Chris","family":"Eades","sequence":"additional","affiliation":[]},{"given":"Laura","family":"Ferreras-Antolin","sequence":"additional","affiliation":[]},{"given":"Rebecca","family":"Gorton","sequence":"additional","affiliation":[]},{"given":"Ronan","family":"McMullan","sequence":"additional","affiliation":[]},{"given":"Iain","family":"Page","sequence":"additional","affiliation":[]},{"given":"Nelun","family":"Perera","sequence":"additional","affiliation":[]},{"given":"Riina","family":"Rautemaa-Richardson","sequence":"additional","affiliation":[]},{"given":"Johannes","family":"Wagener","sequence":"additional","affiliation":[]},{"given":"P","family":"Lewis White","sequence":"additional","affiliation":[]},{"given":"David W","family":"Denning","sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2025,11]]},"member":"78","prefix":"10.1016","source":"Crossref","volume":null,"created":{"date-time":"2025-11-11T12:34:33Z","timestamp":1762864473000,"date-parts":[[2025,11,11]]},"indexed":{"date-time":"2025-11-21T23:04:50Z","timestamp":1763766290450,"date-parts":[[2025,11,21]]},"license":[{"URL":"https://www.elsevier.com/tdm/userlicense/1.0/","start":{"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000,"date-parts":[[2025,11,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.elsevier.com/legal/tdmrep-license","start":{"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000,"date-parts":[[2025,11,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://doi.org/10.15223/policy-017","start":{"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000,"date-parts":[[2025,11,1]]},"delay-in-days":0,"content-version":"stm-asf"},{"URL":"https://doi.org/10.15223/policy-037","start":{"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000,"date-parts":[[2025,11,1]]},"delay-in-days":0,"content-version":"stm-asf"},{"URL":"https://doi.org/10.15223/policy-012","start":{"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000,"date-parts":[[2025,11,1]]},"delay-in-days":0,"content-version":"stm-asf"},{"URL":"https://doi.org/10.15223/policy-029","start":{"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000,"date-parts":[[2025,11,1]]},"delay-in-days":0,"content-version":"stm-asf"},{"URL":"https://doi.org/10.15223/policy-004","start":{"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000,"date-parts":[[2025,11,1]]},"delay-in-days":0,"content-version":"stm-asf"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://linkinghub.elsevier.com/retrieve/pii/S147330992500550X"}},"subtitle":[],"assertion":[{"name":"publisher","label":"This article is maintained by","value":"Elsevier"},{"name":"articletitle","label":"Article Title","value":"British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases: 2025 update"},{"name":"journaltitle","label":"Journal Title","value":"The Lancet Infectious Diseases"},{"name":"articlelink","label":"CrossRef DOI link to publisher maintained version","value":"https://doi.org/10.1016/S1473-3099(25)00550-X"},{"name":"content_type","label":"Content Type","value":"article"},{"name":"copyright","label":"Copyright","value":"© 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies."}],"deposited":{"date-time":"2025-11-21T22:55:08Z","timestamp":1763765708000,"date-parts":[[2025,11,21]]},"issn-type":[{"type":"print","value":"1473-3099"}],"published":{"date-parts":[[2025,11]]},"publisher":"Elsevier BV","reference":[{"DOI":"10.1016/S1473-3099(23)00692-8","key":"10.1016/S1473-3099(25)00550-X_bib1","year":"2024","issue":null,"author":"Denning","volume":"24","first-page":"e428","unstructured":null,"article-title":"Global incidence and mortality of severe fungal disease","journal-title":"Lancet Infect Dis","doi-asserted-by":"crossref"},{"DOI":"10.1016/S1473-3099(15)70006-X","key":"10.1016/S1473-3099(25)00550-X_bib2","year":"2015","issue":null,"author":"Schelenz","volume":"15","first-page":"461","unstructured":null,"article-title":"British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases","journal-title":"Lancet Infect Dis","doi-asserted-by":"crossref"},{"DOI":"10.1093/mmy/myac081","key":"10.1016/S1473-3099(25)00550-X_bib3","year":"2022","issue":null,"author":"Borman","volume":"60","first-page":null,"unstructured":null,"article-title":"The importance of appropriate processing and direct microscopic examination for the timely diagnosis and management of invasive infections caused by filamentous fungi","journal-title":"Med Mycol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cmi.2023.05.012","key":"10.1016/S1473-3099(25)00550-X_bib4","year":"2023","issue":null,"author":"Knoll","volume":"29","first-page":"1031","unstructured":null,"article-title":"How to use direct microscopy for diagnosing fungal infections","journal-title":"Clin Microbiol Infect","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S1473-3099(25)00550-X_bib5","year":"2021","issue":null,"author":"Wengenack","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"10.1016/S1473-3099(25)00550-X_bib6","year":"2021","issue":null,"author":"Abdolrasouli","volume":null,"first-page":null,"unstructured":null,"article-title":"Processing specimens for fungal culture","journal-title":null,"doi-asserted-by":null},{"DOI":"10.1093/cid/ciz1008","key":"10.1016/S1473-3099(25)00550-X_bib7","year":"2020","issue":null,"author":"Donnelly","volume":"71","first-page":"1367","unstructured":null,"article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","journal-title":"Clin Infect Dis","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S1473-3099(25)00550-X_bib8","year":"2022","issue":null,"author":"Abdolrasouli","volume":null,"first-page":null,"unstructured":null,"article-title":"Microscopic examination of clinical specimens","journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/S1473-3099(19)30312-3","key":"10.1016/S1473-3099(25)00550-X_bib9","year":"2019","issue":null,"author":"Cornely","volume":"19","first-page":"e405","unstructured":null,"article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","journal-title":"Lancet Infect Dis","doi-asserted-by":"crossref"},{"DOI":"10.1016/S1473-3099(21)00203-6","key":"10.1016/S1473-3099(25)00550-X_bib10","year":"2021","issue":null,"author":"Chen","volume":"21","first-page":"e375","unstructured":null,"article-title":"Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM","journal-title":"Lancet Infect Dis","doi-asserted-by":"crossref"},{"DOI":"10.1016/S1473-3099(20)30784-2","key":"10.1016/S1473-3099(25)00550-X_bib11","year":"2021","issue":null,"author":"Hoenigl","volume":"21","first-page":"e246","unstructured":null,"article-title":null,"journal-title":"Lancet Infect Dis","doi-asserted-by":"crossref"},{"DOI":"10.1034/j.1399-3003.2000.15b30.x","key":"10.1016/S1473-3099(25)00550-X_bib12","year":"2000","issue":null,"author":"Andreas","volume":"15","first-page":"407","unstructured":null,"article-title":"Diagnosis of pulmonary aspergillosis using optical brighteners","journal-title":"Eur Respir J","doi-asserted-by":"crossref"},{"DOI":"10.1128/jcm.22.2.292-295.1985","key":"10.1016/S1473-3099(25)00550-X_bib13","year":"1985","issue":null,"author":"Plorde","volume":"22","first-page":"292","unstructured":null,"article-title":"Specimen volume versus yield in the BACTEC blood culture system","journal-title":"J Clin Microbiol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cmi.2019.11.019","key":"10.1016/S1473-3099(25)00550-X_bib14","year":"2020","issue":null,"author":"Vergidis","volume":"26","first-page":"935","unstructured":null,"article-title":"High-volume culture and quantitative real-time PCR for the detection of Aspergillus in sputum","journal-title":"Clin Microbiol Infect","doi-asserted-by":"crossref"},{"DOI":"10.1016/S1473-3099(21)00066-9","key":"10.1016/S1473-3099(25)00550-X_bib15","year":"2021","issue":null,"author":"Jabeen","volume":"21","first-page":"767","unstructured":null,"article-title":"Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis","journal-title":"Lancet Infect Dis","doi-asserted-by":"crossref"},{"DOI":"10.1128/JCM.00913-12","key":"10.1016/S1473-3099(25)00550-X_bib16","year":"2012","issue":null,"author":"Borman","volume":"50","first-page":"2639","unstructured":null,"article-title":"Assessment of accuracy of identification of pathogenic yeasts in microbiology laboratories in the United Kingdom","journal-title":"J Clin Microbiol","doi-asserted-by":"crossref"},{"DOI":"10.1093/jac/dkz568","key":"10.1016/S1473-3099(25)00550-X_bib17","year":"2020","issue":null,"author":"Borman","volume":"75","first-page":"1194","unstructured":null,"article-title":"MIC distributions for amphotericin B, fluconazole, itraconazole, voriconazole, flucytosine and anidulafungin and 35 uncommon pathogenic yeast species from the UK determined using the CLSI broth microdilution method","journal-title":"J Antimicrob Chemother","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S1473-3099(25)00550-X_bib19","year":"2016","issue":null,"author":"Fraser","volume":"54","first-page":"80","unstructured":null,"article-title":"Rapid identification of 6328 isolates of pathogenic yeasts using MALDI-ToF MS and a simplified, rapid extraction procedure that is compatible with the Bruker Biotyper platform and database","journal-title":"Med Mycol","doi-asserted-by":null},{"DOI":"10.1128/JCM.02061-06","key":"10.1016/S1473-3099(25)00550-X_bib20","year":"2007","issue":null,"author":"Linton","volume":"45","first-page":"1152","unstructured":null,"article-title":"Molecular identification of unusual pathogenic yeast isolates by large ribosomal subunit gene sequencing: 2 years of experience at the United Kingdom Mycology Reference Laboratory","journal-title":"J Clin Microbiol","doi-asserted-by":"crossref"},{"DOI":"10.1128/EC.4.3.625-632.2005","key":"10.1016/S1473-3099(25)00550-X_bib21","year":"2005","issue":null,"author":"Balajee","volume":"4","first-page":"625","unstructured":null,"article-title":"Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus","journal-title":"Eukaryot Cell","doi-asserted-by":"crossref"},{"DOI":"10.1128/jcm.00873-23","key":"10.1016/S1473-3099(25)00550-X_bib22","year":"2023","issue":null,"author":"de Hoog","volume":"61","first-page":null,"unstructured":null,"article-title":"A conceptual framework for nomenclatural stability and validity of medically important fungi: a proposed global consensus guideline for fungal name changes supported by ABP, ASM, CLSI, ECMM, ESCMID-EFISG, EUCAST-AFST, FDLC, IDSA, ISHAM, MMSA, and MSGERC","journal-title":"J Clin Microbiol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S1473-3099(24)00749-7","key":"10.1016/S1473-3099(25)00550-X_bib23","year":"2025","issue":null,"author":"Cornely","volume":"25","first-page":"e280","unstructured":null,"article-title":"Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM","journal-title":"Lancet Infect Dis","doi-asserted-by":"crossref"},{"DOI":"10.1016/S1473-3099(24)00429-8","key":"10.1016/S1473-3099(25)00550-X_bib24","year":"2024","issue":null,"author":"Kwizera","volume":"24","first-page":"e782","unstructured":null,"article-title":"Antifungal susceptibility testing: applicability of methods and strategies for improving access in resource-constrained settings","journal-title":"Lancet Infect Dis","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S1473-3099(25)00550-X_bib25","year":"2020","issue":null,"author":"Pelzer","volume":"58","first-page":"268","unstructured":null,"article-title":"Performance of the AsperGenius® PCR assay for detecting azole resistant Aspergillus fumigatus in BAL fluids from allogeneic HSCT recipients: a prospective cohort study from Essen, West Germany","journal-title":"Med Mycol","doi-asserted-by":null},{"DOI":"10.3201/eid2001.130906","key":"10.1016/S1473-3099(25)00550-X_bib26","year":"2014","issue":null,"author":"Boulware","volume":"20","first-page":"45","unstructured":null,"article-title":"Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast","journal-title":"Emerg Infect Dis","doi-asserted-by":"crossref"},{"DOI":"10.1093/cid/cix872","key":"10.1016/S1473-3099(25)00550-X_bib27","year":"2018","issue":null,"author":"Wake","volume":"66","first-page":"686","unstructured":null,"article-title":"High cryptococcal antigen titers in blood are predictive of subclinical cryptococcal meningitis among human immunodeficiency virus-infected patients","journal-title":"Clin Infect Dis","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cmi.2024.03.031","key":"10.1016/S1473-3099(25)00550-X_bib28","year":"2024","issue":null,"author":"Paccoud","volume":"30","first-page":"937","unstructured":null,"article-title":"Features of cryptococcosis among 652 HIV-seronegative individuals in France: a cross-sectional observational study (2005–2020)","journal-title":"Clin Microbiol Infect","doi-asserted-by":"crossref"},{"DOI":"10.1093/mmy/myx010","key":"10.1016/S1473-3099(25)00550-X_bib29","year":"2018","issue":null,"author":"Oshima","volume":"56","first-page":"88","unstructured":null,"article-title":"Examination of cryptococcal glucuronoxylomannan antigen in bronchoalveolar lavage fluid for diagnosing pulmonary cryptococcosis in HIV-negative patients","journal-title":"Med Mycol","doi-asserted-by":"crossref"},{"DOI":"10.1128/JCM.02837-20","key":"10.1016/S1473-3099(25)00550-X_bib30","year":"2021","issue":null,"author":"Shi","volume":"59","first-page":"e02837","unstructured":null,"article-title":"Neglecting genetic diversity hinders timely diagnosis of Cryptococcus infections","journal-title":"J Clin Microbiol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S1473-3099(23)00731-4","key":"10.1016/S1473-3099(25)00550-X_bib31","year":"2024","issue":null,"author":"Chang","volume":"24","first-page":"e495","unstructured":null,"article-title":"Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM","journal-title":"Lancet Infect Dis","doi-asserted-by":"crossref"},{"DOI":"10.1093/mmy/myad061","key":"10.1016/S1473-3099(25)00550-X_bib32","year":"2023","issue":null,"author":"Lamoth","volume":"61","first-page":null,"unstructured":null,"article-title":"Performance of the beta-glucan test for the diagnosis of invasive fusariosis and scedosporiosis: a meta-analysis","journal-title":"Med Mycol","doi-asserted-by":"crossref"},{"DOI":"10.3390/ijms18061124","key":"10.1016/S1473-3099(25)00550-X_bib33","year":"2017","issue":null,"author":"McCarthy","volume":"18","first-page":null,"unstructured":null,"article-title":"Translational development and application of (1→3)-β-d-glucan for diagnosis and therapeutic monitoring of invasive mycoses","journal-title":"Int J Mol Sci","doi-asserted-by":"crossref"},{"DOI":"10.3390/jof7010014","key":"10.1016/S1473-3099(25)00550-X_bib34","year":"2020","issue":null,"author":"Finkelman","volume":"7","first-page":"14","unstructured":null,"article-title":"Specificity influences in (1→3)-β-d-glucan-supported diagnosis of invasive fungal disease","journal-title":"J Fungi","doi-asserted-by":"crossref"},{"DOI":"10.1093/jac/dkw156","key":"10.1016/S1473-3099(25)00550-X_bib35","year":"2016","issue":null,"author":"Alanio","volume":"71","first-page":"2386","unstructured":null,"article-title":"ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients","journal-title":"J Antimicrob Chemother","doi-asserted-by":"crossref"},{"DOI":"10.1093/ofid/ofac234","key":"10.1016/S1473-3099(25)00550-X_bib36","year":"2022","issue":null,"author":"Chakrabarti","volume":"9","first-page":null,"unstructured":null,"article-title":"The role of diagnostics-driven antifungal stewardship in the management of invasive fungal infections: a systematic literature review","journal-title":"Open Forum Infect Dis","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S1473-3099(25)00550-X_bib37","year":"2015","issue":null,"author":"Leeflang","volume":"12","first-page":null,"unstructured":null,"article-title":"Galactomannan detection for invasive aspergillosis in immunocompromised patients","journal-title":"Cochrane Database Syst Rev","doi-asserted-by":null},{"DOI":"10.1128/JCM.06423-11","key":"10.1016/S1473-3099(25)00550-X_bib38","year":"2012","issue":null,"author":"D'Haese","volume":"50","first-page":"1258","unstructured":null,"article-title":"Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity","journal-title":"J Clin Microbiol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cmi.2018.01.002","key":"10.1016/S1473-3099(25)00550-X_bib39","year":"2018","issue":"suppl 1","author":"Ullmann","volume":"24","first-page":"e1","unstructured":null,"article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","journal-title":"Clin Microbiol Infect","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cmi.2019.05.019","key":"10.1016/S1473-3099(25)00550-X_bib40","year":"2019","issue":null,"author":"Warris","volume":"25","first-page":"1096","unstructured":null,"article-title":"ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children","journal-title":"Clin Microbiol Infect","doi-asserted-by":"crossref"},{"DOI":"10.3390/jof9060674","key":"10.1016/S1473-3099(25)00550-X_bib41","year":"2023","issue":null,"author":"Bukkems","volume":"9","first-page":"674","unstructured":null,"article-title":"The use of galactomannan antigen assays for the diagnosis of invasive pulmonary aspergillosis in the hematological patient: a systematic review and meta-analysis","journal-title":"J Fungi","doi-asserted-by":"crossref"},{"DOI":"10.1128/JCM.00750-11","key":"10.1016/S1473-3099(25)00550-X_bib42","year":"2012","issue":null,"author":"Bergeron","volume":"50","first-page":"823","unstructured":null,"article-title":"Prospective evaluation of clinical and biological markers to predict the outcome of invasive pulmonary aspergillosis in hematological patients","journal-title":"J Clin Microbiol","doi-asserted-by":"crossref"},{"DOI":"10.1200/JCO.2002.07.004","key":"10.1016/S1473-3099(25)00550-X_bib43","year":"2002","issue":null,"author":"Herbrecht","volume":"20","first-page":"1898","unstructured":null,"article-title":"Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients","journal-title":"J Clin Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1183/13993003.00583-2015","key":"10.1016/S1473-3099(25)00550-X_bib44","year":"2016","issue":null,"author":"Denning","volume":"47","first-page":"45","unstructured":null,"article-title":"Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management","journal-title":"Eur Respir J","doi-asserted-by":"crossref"},{"DOI":"10.1183/13993003.00061-2024","key":"10.1016/S1473-3099(25)00550-X_bib45","year":"2024","issue":null,"author":"Agarwal","volume":"63","first-page":null,"unstructured":null,"article-title":"Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses","journal-title":"Eur Respir J","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cmi.2023.02.002","key":"10.1016/S1473-3099(25)00550-X_bib46","year":"2023","issue":null,"author":"Lu","volume":"29","first-page":"797e1","unstructured":null,"article-title":"The clinical value of Aspergillus-specific IgG antibody test in the diagnosis of nonneutropenic invasive pulmonary aspergillosis","journal-title":"Clin Microbiol Infect","doi-asserted-by":"crossref"},{"DOI":"10.1177/14799731251326592","key":"10.1016/S1473-3099(25)00550-X_bib47","year":"2025","issue":null,"author":"Hatim","volume":"22","first-page":null,"unstructured":null,"article-title":"Aspergillus IgG antibody testing in the diagnosis of hypersensitivity pneumonitis: a scoping review","journal-title":"Chron Respir Dis","doi-asserted-by":"crossref"},{"DOI":"10.1128/JCM.02690-14","key":"10.1016/S1473-3099(25)00550-X_bib48","year":"2015","issue":null,"author":"Oliva","volume":"53","first-page":"248","unstructured":null,"article-title":"Evaluation of the Aspergillus Western blot IgG kit for diagnosis of chronic aspergillosis","journal-title":"J Clin Microbiol","doi-asserted-by":"crossref"},{"DOI":"10.3390/jof7040311","key":"10.1016/S1473-3099(25)00550-X_bib49","year":"2021","issue":null,"author":"Rozaliyani","volume":"7","first-page":"311","unstructured":null,"article-title":"Performance of LDBio Aspergillus WB and ICT antibody detection in chronic pulmonary aspergillosis","journal-title":"J Fungi","doi-asserted-by":"crossref"},{"DOI":"10.1111/myc.13035","key":"10.1016/S1473-3099(25)00550-X_bib50","year":"2020","issue":null,"author":"Wang","volume":"63","first-page":"181","unstructured":null,"article-title":"Diagnostic value of Candida mannan antigen and anti-mannan IgG and IgM antibodies for Candida infection","journal-title":"Mycoses","doi-asserted-by":"crossref"},{"DOI":"10.1093/jac/dkv090","key":"10.1016/S1473-3099(25)00550-X_bib51","year":"2015","issue":null,"author":"Martínez-Jiménez","volume":"70","first-page":"2354","unstructured":null,"article-title":"Candida biomarkers in patients with candidaemia and bacteraemia","journal-title":"J Antimicrob Chemother","doi-asserted-by":"crossref"},{"DOI":"10.3390/jof9080813","key":"10.1016/S1473-3099(25)00550-X_bib52","year":"2023","issue":null,"author":"Eades","volume":"9","first-page":"813","unstructured":null,"article-title":"Comparison of β-1–3-d-glucan and Candida mannan biomarker assays with serological tests for the diagnosis of candidemia","journal-title":"J Fungi","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.alit.2023.07.003","key":"10.1016/S1473-3099(25)00550-X_bib53","year":"2023","issue":null,"author":"Denning","volume":"72","first-page":"493","unstructured":null,"article-title":"Poorly controlled asthma - easy wins and future prospects for addressing fungal allergy","journal-title":"Allergol Int","doi-asserted-by":"crossref"},{"DOI":"10.1371/journal.pone.0098502","key":"10.1016/S1473-3099(25)00550-X_bib54","year":"2014","issue":null,"author":"Armstead","volume":"9","first-page":null,"unstructured":null,"article-title":"Multi-country estimate of different manifestations of aspergillosis in cystic fibrosis","journal-title":"PLoS One","doi-asserted-by":"crossref"},{"DOI":"10.1093/cid/ciae239","key":"10.1016/S1473-3099(25)00550-X_bib55","year":"2024","issue":null,"author":"Brown","volume":"79","first-page":"161","unstructured":null,"article-title":"Polymerase chain reaction on respiratory tract specimens of immunocompromised patients to diagnose Pneumocystis pneumonia: a systematic review and meta-analysis","journal-title":"Clin Infect Dis","doi-asserted-by":"crossref"},{"DOI":"10.1093/mmy/myaf023","key":"10.1016/S1473-3099(25)00550-X_bib56","year":"2025","issue":null,"author":"Ghelfenstein-Ferreira","volume":"63","first-page":null,"unstructured":null,"article-title":"Multicentric prospective evaluation of Pneumocystis jirovecii fungal load in bronchoalveolar lavage fluid fractions using qPCR","journal-title":"Med Mycol","doi-asserted-by":"crossref"},{"DOI":"10.1093/mmy/myz115","key":"10.1016/S1473-3099(25)00550-X_bib57","year":"2020","issue":null,"author":"Gits-Muselli","volume":"58","first-page":"779","unstructured":null,"article-title":"The Fungal PCR Initiative's evaluation of in-house and commercial Pneumocystis jirovecii qPCR assays: toward a standard for a diagnostics assay","journal-title":"Med Mycol","doi-asserted-by":"crossref"},{"DOI":"10.1128/JCM.00905-15","key":"10.1016/S1473-3099(25)00550-X_bib58","year":"2015","issue":null,"author":"White","volume":"53","first-page":"2832","unstructured":null,"article-title":"Clinical performance of Aspergillus PCR for testing serum and plasma: a study by the European Aspergillus PCR Initiative","journal-title":"J Clin Microbiol","doi-asserted-by":"crossref"},{"DOI":"10.1128/JCM.02814-15","key":"10.1016/S1473-3099(25)00550-X_bib59","year":"2016","issue":null,"author":"Springer","volume":"54","first-page":"705","unstructured":null,"article-title":"Comparison of performance characteristics of Aspergillus PCR in testing a range of blood-based samples in accordance with international methodological recommendations","journal-title":"J Clin Microbiol","doi-asserted-by":"crossref"},{"DOI":"10.1128/JCM.01767-09","key":"10.1016/S1473-3099(25)00550-X_bib60","year":"2010","issue":null,"author":"White","volume":"48","first-page":"1231","unstructured":null,"article-title":"Aspergillus PCR: one step closer to standardization","journal-title":"J Clin Microbiol","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S1473-3099(25)00550-X_bib61","year":"2019","issue":null,"author":"Cruciani","volume":"9","first-page":null,"unstructured":null,"article-title":"Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people","journal-title":"Cochrane Database Syst Rev","doi-asserted-by":null},{"DOI":"10.1093/cid/ciaa1865","key":"10.1016/S1473-3099(25)00550-X_bib62","year":"2021","issue":"suppl 2","author":"White","volume":"72","first-page":"S95","unstructured":null,"article-title":"Aspergillus polymerase chain reaction-an update on technical recommendations, clinical applications, and justification for inclusion in the second revision of the EORTC/MSGERC definitions of invasive fungal disease","journal-title":"Clin Infect Dis","doi-asserted-by":"crossref"},{"DOI":"10.1186/s12890-023-02343-5","key":"10.1016/S1473-3099(25)00550-X_bib63","year":"2023","issue":null,"author":"Han","volume":"23","first-page":"58","unstructured":null,"article-title":"Bronchoalveolar lavage fluid polymerase chain reaction for invasive pulmonary aspergillosis among high-risk patients: a diagnostic meta-analysis","journal-title":"BMC Pulm Med","doi-asserted-by":"crossref"},{"DOI":null,"key":"10.1016/S1473-3099(25)00550-X_bib64","year":"2007","issue":null,"author":"Tuon","volume":"24","first-page":"89","unstructured":null,"article-title":"A systematic literature review on the diagnosis of invasive aspergillosis using polymerase chain reaction (PCR) from bronchoalveolar lavage clinical samples","journal-title":"Rev Iberoam Micol","doi-asserted-by":null},{"DOI":"10.1371/journal.pone.0028467","key":"10.1016/S1473-3099(25)00550-X_bib65","year":"2011","issue":null,"author":"Sun","volume":"6","first-page":null,"unstructured":null,"article-title":"Evaluation of PCR on bronchoalveolar lavage fluid for diagnosis of invasive aspergillosis: a bivariate metaanalysis and systematic review","journal-title":"PLoS One","doi-asserted-by":"crossref"},{"DOI":"10.1128/JCM.00942-12","key":"10.1016/S1473-3099(25)00550-X_bib66","year":"2012","issue":null,"author":"Avni","volume":"50","first-page":"3652","unstructured":null,"article-title":"Diagnostic accuracy of PCR alone compared to galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis: a systematic review","journal-title":"J Clin Microbiol","doi-asserted-by":"crossref"},{"DOI":"10.1128/JCM.01602-10","key":"10.1016/S1473-3099(25)00550-X_bib67","year":"2011","issue":null,"author":"Avni","volume":"49","first-page":"665","unstructured":null,"article-title":"PCR diagnosis of invasive candidiasis: systematic review and meta-analysis","journal-title":"J Clin Microbiol","doi-asserted-by":"crossref"},{"DOI":"10.1128/JCM.01909-17","key":"10.1016/S1473-3099(25)00550-X_bib68","year":"2018","issue":null,"author":"Clancy","volume":"56","first-page":"e01909","unstructured":null,"article-title":"Diagnosing invasive candidiasis","journal-title":"J Clin Microbiol","doi-asserted-by":"crossref"},{"DOI":"10.1093/jac/dkac161","key":"10.1016/S1473-3099(25)00550-X_bib69","year":"2022","issue":null,"author":"Rogers","volume":"77","first-page":"2053","unstructured":null,"article-title":"Molecular mechanisms of acquired antifungal drug resistance in principal fungal pathogens and EUCAST guidance for their laboratory detection and clinical implications","journal-title":"J Antimicrob Chemother","doi-asserted-by":"crossref"},{"DOI":"10.1128/jcm.00158-24","key":"10.1016/S1473-3099(25)00550-X_bib70","year":"2024","issue":null,"author":"Franco","volume":"62","first-page":null,"unstructured":null,"article-title":"Validation of a qualitative real-time PCR assay for the detection of Candida auris in hospital inpatient screening","journal-title":"J Clin Microbiol","doi-asserted-by":"crossref"},{"DOI":"10.1128/JCM.00630-19","key":"10.1016/S1473-3099(25)00550-X_bib71","year":"2019","issue":null,"author":"Leach","volume":"57","first-page":"e00630","unstructured":null,"article-title":"A rapid and automated sample-to-result Candida auris real-time pcr assay for high-throughput testing of surveillance samples with the BD Max open system","journal-title":"J Clin Microbiol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.eclinm.2025.103115","key":"10.1016/S1473-3099(25)00550-X_bib72","year":"2025","issue":null,"author":"Brown","volume":"81","first-page":null,"unstructured":null,"article-title":"The diagnosis of mucormycosis by PCR in patients at risk: a systematic review and meta-analysis","journal-title":"EClinicalMedicine","doi-asserted-by":"crossref"},{"DOI":"10.1111/myc.12837","key":"10.1016/S1473-3099(25)00550-X_bib73","year":"2018","issue":null,"author":"Gholinejad-Ghadi","volume":"61","first-page":"909","unstructured":null,"article-title":"Identification of Mucorales in patients with proven invasive mucormycosis by polymerase chain reaction in tissue samples","journal-title":"Mycoses","doi-asserted-by":"crossref"},{"DOI":"10.1093/mmy/myae030","key":"10.1016/S1473-3099(25)00550-X_bib74","year":"2024","issue":null,"author":"Bellanger","volume":"62","first-page":null,"unstructured":null,"article-title":"Use of the Mucorales qPCR on blood to screen high-risk hematology patients is associated with better survival","journal-title":"Med Mycol","doi-asserted-by":"crossref"},{"DOI":"10.1093/mmy/myac004","key":"10.1016/S1473-3099(25)00550-X_bib75","year":"2022","issue":null,"author":"Clark","volume":"60","first-page":null,"unstructured":null,"article-title":"Assessment of panfungal PCR performance with formalin-fixed paraffin-embedded tissue specimens","journal-title":"Med Mycol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.pathol.2023.03.011","key":"10.1016/S1473-3099(25)00550-X_bib76","year":"2023","issue":null,"author":"Sparks","volume":"55","first-page":"669","unstructured":null,"article-title":"Panfungal PCR on formalin-fixed, paraffin-embedded tissue: to proceed or not proceed?","journal-title":"Pathology","doi-asserted-by":"crossref"},{"DOI":"10.1164/rccm.202305-0901OC","key":"10.1016/S1473-3099(25)00550-X_bib77","year":"2024","issue":null,"author":"Charalampous","volume":"209","first-page":"164","unstructured":null,"article-title":"Routine metagenomics service for ICU patients with respiratory infection","journal-title":"Am J Respir Crit Care Med","doi-asserted-by":"crossref"},{"DOI":"10.1093/jac/dkt508","key":"10.1016/S1473-3099(25)00550-X_bib78","year":"2014","issue":null,"author":"Ashbee","volume":"69","first-page":"1162","unstructured":null,"article-title":"Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology","journal-title":"J Antimicrob Chemother","doi-asserted-by":"crossref"},{"DOI":"10.1097/FTD.0000000000000931","key":"10.1016/S1473-3099(25)00550-X_bib79","year":"2022","issue":null,"author":"Kim","volume":"44","first-page":"198","unstructured":null,"article-title":"Therapeutic drug monitoring of the echinocandin antifungal agents: is there a role in clinical practice? A position statement of the Anti-Infective Drugs Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology","journal-title":"Ther Drug Monit","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.mmcr.2012.12.006","key":"10.1016/S1473-3099(25)00550-X_bib80","year":"2012","issue":null,"author":"Koch","volume":"2","first-page":"23","unstructured":null,"article-title":"Insufficient serum caspofungin levels in a paediatric patient on ECMO","journal-title":"Med Mycol Case Rep","doi-asserted-by":"crossref"},{"DOI":"10.1007/s40262-023-01264-0","key":"10.1016/S1473-3099(25)00550-X_bib81","year":"2023","issue":null,"author":"Lyster","volume":"62","first-page":"931","unstructured":null,"article-title":"Antifungal dosing in critically ill patients on extracorporeal membrane oxygenation","journal-title":"Clin Pharmacokinet","doi-asserted-by":"crossref"},{"DOI":"10.1093/jac/dkad293","key":"10.1016/S1473-3099(25)00550-X_bib82","year":"2023","issue":null,"author":"Boglione-Kerrien","volume":"78","first-page":"2630","unstructured":null,"article-title":"Can we predict the influence of inflammation on voriconazole exposure? An overview","journal-title":"J Antimicrob Chemother","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ijantimicag.2023.106750","key":"10.1016/S1473-3099(25)00550-X_bib83","year":"2023","issue":null,"author":"van den Born","volume":"61","first-page":null,"unstructured":null,"article-title":"Voriconazole exposure is influenced by inflammation: a population pharmacokinetic model","journal-title":"Int J Antimicrob Agents","doi-asserted-by":"crossref"},{"DOI":"10.1007/s40272-023-00616-4","key":"10.1016/S1473-3099(25)00550-X_bib84","year":"2024","issue":null,"author":"Taher","volume":"26","first-page":"197","unstructured":null,"article-title":"Therapeutic drug monitoring of voriconazole in critically ill pediatric patients: a single-center retrospective study","journal-title":"Paediatr Drugs","doi-asserted-by":"crossref"},{"DOI":"10.1002/jcph.2254","key":"10.1016/S1473-3099(25)00550-X_bib85","year":"2023","issue":null,"author":"Xie","volume":"63","first-page":"993","unstructured":null,"article-title":"Optimization of voriconazole dosing regimens against Aspergillus species and Candida species in pediatric patients after hematopoietic cell transplantation: a theoretical study based on pharmacokinetic/pharmacodynamic analysis","journal-title":"J Clin Pharmacol","doi-asserted-by":"crossref"},{"DOI":"10.1128/aac.00829-23","key":"10.1016/S1473-3099(25)00550-X_bib86","year":"2023","issue":null,"author":"Fernández Ledesma","volume":"67","first-page":null,"unstructured":null,"article-title":"Isavuconazole use and TDM in real-world pediatric practice","journal-title":"Antimicrob Agents Chemother","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.cmi.2016.04.022","key":"10.1016/S1473-3099(25)00550-X_bib87","year":"2016","issue":null,"author":"Aye","volume":"22","first-page":"632","unstructured":null,"article-title":"Cryptococcosis-the impact of delay to diagnosis","journal-title":"Clin Microbiol Infect","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.eclinm.2020.100563","key":"10.1016/S1473-3099(25)00550-X_bib88","year":"2020","issue":null,"author":"Salazar","volume":"27","first-page":null,"unstructured":null,"article-title":"Potential missed opportunities for diagnosis of cryptococcosis and the association with mortality: a cohort study","journal-title":"EClinicalMedicine","doi-asserted-by":"crossref"},{"DOI":"10.5334/aogh.3524","key":"10.1016/S1473-3099(25)00550-X_bib89","year":"2022","issue":null,"author":"Link","volume":"88","first-page":"22","unstructured":null,"article-title":"Delays in cryptococcal meningitis diagnosis and care: a mixed methods study in rural Uganda","journal-title":"Ann Glob Health","doi-asserted-by":"crossref"},{"DOI":"10.1111/myc.12628","key":"10.1016/S1473-3099(25)00550-X_bib90","year":"2017","issue":null,"author":"Cornely","volume":"60","first-page":"420","unstructured":null,"article-title":"Improving outcome of fungal diseases - guiding experts and patients towards excellence","journal-title":"Mycoses","doi-asserted-by":"crossref"},{"DOI":"10.1056/NEJMp1606458","key":"10.1016/S1473-3099(25)00550-X_bib91","year":"2016","issue":null,"author":"Bohmer","volume":"375","first-page":"709","unstructured":null,"article-title":"The hard work of health care transformation","journal-title":"N Engl J Med","doi-asserted-by":"crossref"}],"updated-by":[{"DOI":"10.1016/s1473-3099(25)00724-8","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000,"date-parts":[[2025,11,19]]}}],"short-title":[],"update-policy":"https://doi.org/10.1016/elsevier_cm_policy","alternative-id":["S147330992500550X"],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"original-title":[],"container-title":["The Lancet Infectious Diseases"],"published-print":{"date-parts":[[2025,11]]},"reference-count":90,"published-online":null,"references-count":90,"short-container-title":["The Lancet Infectious Diseases"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1016/s1473-3099(25)00550-x","is_oa":false,"title":"British Society for Medical Mycology best practice recommendations for the diagnosis of serious fungal diseases: 2025 update","updated":"2025-11-13T08:10:39+00:00","published_date":"2025-11-01","best_oa_location":null}},"created_at":"2025-12-04T03:42:26.941Z","updated_at":"2025-12-04T03:42:26.941Z","tags":[{"paper_doi":"10.1016/s1473-3099(25)00550-x","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(25)00550-x","tag_type":"category","value":"Infectious Diseases","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(25)00550-x","tag_type":"condition","value":"Aspergillosis","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(25)00550-x","tag_type":"condition","value":"Invasive Candidiasis","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(25)00550-x","tag_type":"condition","value":"Invasive Fungal Disease","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(25)00550-x","tag_type":"condition","value":"Mucormycosis","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(25)00550-x","tag_type":"condition","value":"Pneumocystis Pneumonia","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(25)00550-x","tag_type":"generic","value":"isavuconazole","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(25)00550-x","tag_type":"generic","value":"posaconazole","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(25)00550-x","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(25)00550-x","tag_type":"study_design","value":"Guideline","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(25)00550-x","tag_type":"warning","value":"No sample size or quantitative performance metrics are provided in the abstract.","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(25)00550-x","tag_type":"warning","value":"Specific indications and thresholds for individual tests are not detailed in the abstract.","value_numeric":null},{"paper_doi":"10.1016/s1473-3099(25)00550-x","tag_type":"warning","value":"This is an expert consensus guideline, not a clinical trial with outcomes.","value_numeric":null}],"summaries":{"what_studied":"An expert group updated best practice recommendations for diagnosing serious fungal diseases in the UK, focusing on adults, with test-specific guidance and expected turnaround times; histopathology and radiology guidance remain as in 2015.","key_result":"New or stronger recommendations: use Pneumocystis PCR; use 1,3-β-D-glucan for suspected invasive candidiasis and Pneumocystis pneumonia; collect higher-volume respiratory samples for culture; broaden Aspergillus antigen/antibody testing to ICU patients and those with chronic respiratory disease (including asthma); use Candida PCR and Mucorales PCR in specific contexts; apply pan-fungal PCR/DNA sequencing for identification from positive microscopy or histopathology; include posaconazole and isavuconazole in therapeutic drug monitoring.","limitations":"Access to tests and turnaround times vary across the UK, which may limit implementation; recommendations focus on adults and UK practice, with pediatric and global applicability only discussed, not specified.","practice_takeaway":"Adopt non-culture diagnostics alongside stewardship: order Pneumocystis PCR and 1,3-β-D-glucan when PCP or invasive candidiasis is suspected; use higher-volume respiratory cultures; expand Aspergillus antigen/antibody testing to ICU and chronic lung disease; consider Candida and Mucorales PCR where appropriate; use pan-fungal PCR/sequencing when microscopy or histology is positive; monitor posaconazole and isavuconazole levels."}}],"initialOffset":6,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Invasive Candidiasis"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Invasive Candidiasis"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Invasive Candidiasis"}}}]]

Papers